Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) "CONDUCTOME"

Grenoble Alpes University Hospital Center (CHU)

Status and phase: Terminated; Phase 1

Conditions: Cerebral Primitive Tumor With Chirurgical Indication

Treatments: Other: MEG and MRI

Study type: Interventional

Funder types: Other

Identifiers

NCT02077504

CONDUCTOME

Details and patient eligibility

About

The purpose of this study is to determine the correlation between functional MEG analysis of the tumor and its periphery and the tumor stage and treatment response.

Full description

A better tumor grade definition would provide an optimized surgical care, prognosis and therapeutical response evaluation.

Enrollment: 28 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• more or equal than 18 years old
• patient affiliated to social security or similarly regime
• informed consent form signed
• supra-tentorial primitive cerebral tumor

Exclusion criteria

• Pregnant women and lactating mothers
• Ward of court or under guardianship
• Adult unable to express their consent
• Person deprived of freedom by judicial or administrative decision
• Person hospitalized without their consent
• Person under legal protection
• Magnetic Resonance Imaging (MRI) contraindication (implanted material non MRI-compatible, ferro-magnetic foreign body, claustrophobia)
• Patients needed emergency medical care for other pathology
• severely altered general health (Performance Status 3 or 4)

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

28 participants in 1 patient group

CONDUCTOME

Experimental group

Description:

MEG and MRI

Treatment:

Other: MEG and MRI